Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment

Pallavi Madhiraju- July 14, 2024 0

Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial. The ... Read More

Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment

Pallavi Madhiraju- July 7, 2024 0

Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in ... Read More

Antengene’s XPOVIO approved in China for diffuse large B-cell lymphoma

Pallavi Madhiraju- July 5, 2024 0

Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication ... Read More

Ascentage Pharma receives $100m payment from Takeda under exclusive option agreement

Pallavi Madhiraju- July 4, 2024 0

Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million ... Read More

Signet Therapeutics gets FDA IND approval for sigx1094 in diffuse gastric cancer

Pallavi Madhiraju- July 2, 2024 0

Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)'s Investigational New Drug (IND) approval of ... Read More

Exploring Marine Cytotoxic Compounds in Cancer Treatment

pharmanewsdaily- June 15, 2024 0

Marine organisms offer a vast reservoir of cytotoxic compounds with potential therapeutic applications in treating various cancers. These biomedicines, known as marine drugs, are derived ... Read More

FDA grants accelerated approval for Bristol Myers Squibb’s Augtyro for NTRK-positive tumors

Pallavi Madhiraju- June 14, 2024 0

Bristol Myers Squibb (NYSE: BMY) has received accelerated FDA approval for Augtyro (repotrectinib), a treatment designed for patients 12 years and older with NTRK gene ... Read More

AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment

Pallavi Madhiraju- June 6, 2024 0

AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating ... Read More

FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment

Pallavi Madhiraju- June 4, 2024 0

FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in ... Read More

CStone’s sugemalimab gains CHMP recommendation for NSCLC treatment

Pallavi Madhiraju- June 2, 2024 0

CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ... Read More

1234...820 / 78 Posts